Ludovic Alonzi Bio

Ludovic Alonzi joined ARCHIMED in 2016 and was appointed as Partner in 2025. Ludovic brings nine years of experience in M&A advisory, gained at Marceau Finance and later at Alira Health, where he specialized in small and mid-cap healthcare transactions across Europe. At ARCHIMED, Ludovic has developed deep expertise in the Life Sciences sector, notably contributing as a Board member to the growth and strategic development of companies such as Polyplus, Clean Biologics, and Xpress Biologics. In 2023, he further expanded his operational leadership by completing a secondment at Stragen, a generics pharmaceutical company, where he successfully led the group’s reorganization as acting CEO.